CanSino Biologics Past Earnings Performance
Past criteria checks 0/6
CanSino Biologics's earnings have been declining at an average annual rate of -32.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 15.4% per year.
Key information
-32.1%
Earnings growth rate
-30.5%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 15.4% |
Return on equity | -18.1% |
Net Margin | -136.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?
Jun 20The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%
Jan 11Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?
Dec 26Revenue & Expenses Breakdown
How CanSino Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 635 | -867 | 580 | 486 |
31 Mar 24 | 371 | -1,513 | 619 | 585 |
31 Dec 23 | 357 | -1,483 | 655 | 638 |
30 Sep 23 | 503 | -1,420 | 573 | 691 |
30 Jun 23 | 431 | -1,763 | 599 | 793 |
31 Mar 23 | 636 | -1,170 | 569 | 771 |
31 Dec 22 | 1,035 | -909 | 544 | 778 |
30 Sep 22 | 1,921 | 106 | 487 | 772 |
30 Jun 22 | 2,868 | 989 | 434 | 651 |
31 Mar 22 | 4,332 | 2,050 | 408 | 766 |
31 Dec 21 | 4,300 | 1,914 | 329 | 879 |
30 Sep 21 | 3,105 | 1,113 | 246 | 908 |
30 Jun 21 | 2,082 | 643 | 187 | 872 |
31 Mar 21 | 488 | -388 | 103 | 659 |
31 Dec 20 | 25 | -397 | 95 | 428 |
30 Sep 20 | 6 | -239 | 75 | 234 |
30 Jun 20 | 4 | -189 | 64 | 202 |
31 Mar 20 | 6 | -135 | 79 | 191 |
31 Dec 19 | 2 | -157 | 65 | 152 |
30 Sep 19 | 6 | -137 | 66 | 127 |
30 Jun 19 | 11 | -156 | 69 | 122 |
31 Mar 19 | 9 | -158 | 40 | 89 |
31 Dec 18 | 9 | -138 | 46 | 114 |
31 Dec 17 | 9 | -64 | 16 | 68 |
31 Dec 16 | 8 | -50 | 10 | 52 |
Quality Earnings: 6185 is currently unprofitable.
Growing Profit Margin: 6185 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6185 is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.
Accelerating Growth: Unable to compare 6185's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6185 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Return on Equity
High ROE: 6185 has a negative Return on Equity (-18.09%), as it is currently unprofitable.